Research analysts at Citigroup assumed coverage on shares of athenahealth (NASDAQ:ATHN) in a report released on Thursday, The Fly reports. The brokerage set a “neutral” rating on the health services provider’s stock.
Other equities analysts have also issued reports about the stock. Oppenheimer reiterated a “buy” rating and set a $184.00 target price on shares of athenahealth in a report on Friday, October 20th. Piper Jaffray Companies reiterated a “buy” rating and set a $167.00 target price on shares of athenahealth in a report on Tuesday, October 17th. SunTrust Banks reissued a “buy” rating and set a $156.00 price target on shares of athenahealth in a research report on Wednesday, October 25th. Leerink Swann set a $155.00 price target on shares of athenahealth and gave the company a “hold” rating in a research report on Thursday, October 19th. Finally, Jefferies Group reduced their price target on shares of athenahealth from $135.00 to $120.00 and set a “hold” rating for the company in a research report on Friday, September 15th. One analyst has rated the stock with a sell rating, seventeen have given a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $143.29.
Shares of athenahealth (ATHN) opened at $135.37 on Thursday. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.35. athenahealth has a 1-year low of $95.01 and a 1-year high of $158.66. The company has a market cap of $5,438.40, a PE ratio of 175.81, a price-to-earnings-growth ratio of 3.18 and a beta of 1.58.
In other athenahealth news, Director Amy Abernethy sold 500 shares of the business’s stock in a transaction on Tuesday, December 26th. The shares were sold at an average price of $134.18, for a total value of $67,090.00. Following the sale, the director now owns 4,045 shares in the company, valued at approximately $542,758.10. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Bradford Kyle Armbrester sold 1,000 shares of the business’s stock in a transaction on Friday, October 27th. The stock was sold at an average price of $128.56, for a total transaction of $128,560.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 64,700 shares of company stock worth $8,705,472. Corporate insiders own 3.20% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Turner Investments LLC purchased a new stake in shares of athenahealth during the 2nd quarter valued at about $105,000. Parkside Financial Bank & Trust raised its position in shares of athenahealth by 13.0% during the 3rd quarter. Parkside Financial Bank & Trust now owns 811 shares of the health services provider’s stock valued at $102,000 after buying an additional 93 shares in the last quarter. Advisors Asset Management Inc. raised its position in shares of athenahealth by 1.9% during the 3rd quarter. Advisors Asset Management Inc. now owns 895 shares of the health services provider’s stock valued at $113,000 after buying an additional 17 shares in the last quarter. First Quadrant L P CA purchased a new stake in shares of athenahealth during the 3rd quarter valued at about $114,000. Finally, Bessemer Group Inc. raised its position in shares of athenahealth by 13.7% during the 2nd quarter. Bessemer Group Inc. now owns 938 shares of the health services provider’s stock valued at $132,000 after buying an additional 113 shares in the last quarter.
About athenahealth
athenahealth, Inc provides network-based medical record, revenue cycle, patient engagement, care coordination and population health services. The Company also offers Epocrates and other point-of-care mobile applications. The Company delivers majority of its service offerings through a single instance of cloud-based software, athenaNet.
